BI2536 (the first-in-class prototype Plk1 inhibitor) inhibited SmPlk1 kinase activity and induced in vitro dramatic alterations in schistosome gonads, which affected oogenesis and spermatogenesis, suggesting that SmPlk1 could represent a new target against schistosomiasis [23]. Here, PLK1 is linked to schistosomiasis.